GRAL NHS-Galleri Trial Results
Key Fact: GRAL stock plummeted after the NHS-Galleri trial failed to meet its primary endpoint of statistically significant reduction in combined Stage III and Stage IV cancers.
Impact:
GRAL share price dropped by roughly 51% in one day.
Approximately $2.1 billion in market capitalization was lost.
Action:
Monitor upcoming updates on trial data and commercial execution.
Consider market conditions before investing.
